Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

How will COVID-19 affect uptake of vaccinations against other diseases?

Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?

- PMLiVE

Neurofibromatosis: a condition that’s hard to say, but even harder to live with

The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).

Havas Lynx

Do you know what PoTS is?

As part of Dysautonomia Awareness Month, Origins continues its efforts in raising awareness and understanding of Postural Tachycardia Syndrome (PoTS), a Dysautonomia condition affecting young women that can be very...

Bedrock Healthcare Communications

- PMLiVE

St John & St Elizabeth Hospital “Putting people first” by Seven Stones

St John & St Elizabeth Hospital has created it’s first brand campaign for the Hospital and Hospice, bringing to life its new mantra of ‘putting people first’.

SEVEN STONES COLLECTIVE

- PMLiVE

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward

The COVID-19 pandemic has permanently changed how medical education in the healthcare industry is conducted. Over the last few months, all conferences, medical education and field force deliverables have either...

OPEN Health

- PMLiVE

Moderna’s chief exec expects to have COVID-19 vaccine data in November

If data is promising, company could seek emergency use authorisation in the US in December

- PMLiVE

UK government invests in human challenge trials for COVID-19

The trials could begin in 2021 if approved by regulators

- PMLiVE

Novartis scores CHMP backing for cholesterol drug Leqvio

Potential first-in-class treatment moves closer to EU approval

Time to tear down the wallpaper?

By James Mayfield

- PMLiVE

Galapagos mid-stage trial failure raises concerns for Gilead deal

Investigational osteoarthritis treatment misses primary endpoint in phase 2 study

- PMLiVE

WHO trial casts doubt on remdesivir’s efficacy

Drug's developer Gilead hits back at the findings

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links